Press Releases Immunocore Holdings plc

Equities

IMCR

US45258D1054

Real-time Estimate Cboe BZX Other stock markets 03:49:43 2024-06-10 pm EDT			5-day change	1st Jan Change
40.46 ^USD	-2.94%		-5.80%	-41.07%

Jun. 01	Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	CI
Jun. 01	Transcript : Immunocore Holdings plc - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	Jun. 01	AQ
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	Jun. 01	GL
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024	May. 31	GL
Immunocore to present at the Jefferies Global Healthcare Conference	May. 30	GL
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma	May. 29	GL
Immunocore reports first quarter financial results and provides a business update	May. 08	GL
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group	May. 01	AQ
Immunocore announces upcoming presentation and posters at ASCO 2024	Apr. 24	GL
Immunocore to present at upcoming investor conferences	Apr. 04	GL
Immunocore presented two posters at CROI 2024	Mar. 05	GL
Immunocore to present at upcoming investor conferences	Mar. 01	GL
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update	Feb. 28	GL
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial	Feb. 22	GL
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024	Feb. 21	GL
Immunocore Prices Upsized Convertible Senior Notes Offering	Jan. 30	GL
Immunocore Prices Upsized Convertible Senior Notes Offering	Jan. 30	AQ
Immunocore Announces Proposed Convertible Senior Notes Offering	Jan. 29	GL
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation	Jan. 05	GL
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	GL
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immunocore Holdings plc

Equities

IMCR

US45258D1054

Press Releases

Filters